P Cornejo-Juárez1, D Vilar-Compte2, C Pérez-Jiménez2, S A Ñamendys-Silva3, S Sandoval-Hernández2, P Volkow-Fernández2. 1. Department of Infectious Disease, Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14080 México, D.F., Mexico. Electronic address: patcornejo@yahoo.com. 2. Department of Infectious Disease, Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, Tlalpan, 14080 México, D.F., Mexico. 3. Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City, Mexico.
Abstract
OBJECTIVE: To describe overall site-specific hospital-acquired infection (HAI) rates and to describe the microbiological and antibiotic resistance profiles of infecting pathogens, together with their impact on multidrug-resistant (MDR) bacteria-associated mortality. METHODS: We conducted a 5-year retrospective descriptive study of HAI in patients in the intensive care unit (ICU) of a cancer center in Mexico from January 2007 to December 2011. The following information was collected: patient characteristics and comorbidities, data related to the neoplasm and its treatment, microbiology, and the resistance pattern of all isolates. RESULTS: During the study period, 1418 patients were admitted to the ICU; 134 of them developed 159 infections, with an incidence of 11.2/100 hospitalized patients and 32.2/per 1000 patient-days. Two hundred sixty-six microorganisms were isolated. The overall prevalence of MDR-HAI was 39.5%. The most frequent organisms were as follows: 54 (20%) Escherichia coli (94.4% of these were extended-spectrum beta-lactamase producers), 32 (12%) Staphylococcus aureus (90.6% of these were methicillin-resistant), 32 (12%) Enterococcus faecium (18.7% of these were vancomycin-resistant), and 20 (6%) Acinetobacter baumannii (all were MDR). Among patients admitted to the ICU, 252 (17.8%) died. Death was related to the HAI in 58 (23%) of these patients (p<0.001) and 51 (88%) had a MDR organism isolated (p=0.05). CONCLUSIONS: The emergence of MDR bacteria poses a difficult task for physicians, who have limited therapeutic options. Critically ill cancer patients admitted to the ICU are at major risk of a bacterial MDR-HAI that will impact adversely on mortality.
OBJECTIVE: To describe overall site-specific hospital-acquired infection (HAI) rates and to describe the microbiological and antibiotic resistance profiles of infecting pathogens, together with their impact on multidrug-resistant (MDR) bacteria-associated mortality. METHODS: We conducted a 5-year retrospective descriptive study of HAI in patients in the intensive care unit (ICU) of a cancer center in Mexico from January 2007 to December 2011. The following information was collected: patient characteristics and comorbidities, data related to the neoplasm and its treatment, microbiology, and the resistance pattern of all isolates. RESULTS: During the study period, 1418 patients were admitted to the ICU; 134 of them developed 159 infections, with an incidence of 11.2/100 hospitalized patients and 32.2/per 1000 patient-days. Two hundred sixty-six microorganisms were isolated. The overall prevalence of MDR-HAI was 39.5%. The most frequent organisms were as follows: 54 (20%) Escherichia coli (94.4% of these were extended-spectrum beta-lactamase producers), 32 (12%) Staphylococcus aureus (90.6% of these were methicillin-resistant), 32 (12%) Enterococcus faecium (18.7% of these were vancomycin-resistant), and 20 (6%) Acinetobacter baumannii (all were MDR). Among patients admitted to the ICU, 252 (17.8%) died. Death was related to the HAI in 58 (23%) of these patients (p<0.001) and 51 (88%) had a MDR organism isolated (p=0.05). CONCLUSIONS: The emergence of MDR bacteria poses a difficult task for physicians, who have limited therapeutic options. Critically ill cancerpatients admitted to the ICU are at major risk of a bacterial MDR-HAI that will impact adversely on mortality.
Authors: Kirill Gorshkov; Catherine Z Chen; Raisa E Marshall; Nino Mihatov; Yong Choi; Dac-Trung Nguyen; Noel Southall; Kevin G Chen; John K Park; Wei Zheng Journal: Drug Discov Today Date: 2018-08-17 Impact factor: 7.851
Authors: Edwin D Neas; Julie A Dunn; Evelyn Dimaano Silva; A Morgan Chambers; Gary J Luckasen; Adam Jaskowiak Journal: Adv Wound Care (New Rochelle) Date: 2016-10-01 Impact factor: 4.730
Authors: Caitlin L Williams; Heather M Neu; Jeremy J Gilbreath; Sarah L J Michel; Daniel V Zurawski; D Scott Merrell Journal: Appl Environ Microbiol Date: 2016-09-30 Impact factor: 4.792
Authors: Jussyêgles Niedja da Paz Pereira; Carlos Alberto das Neves de Andrade; Jailton Lobo da Costa Lima; Reginaldo Gonçalves de Lima Neto; Paulo Sérgio Ramos de Araújo; Maria Amélia Vieira Maciel Journal: Curr Microbiol Date: 2019-10-26 Impact factor: 2.188
Authors: Wei Sun; Rebecca A Weingarten; Miao Xu; Noel Southall; Sheng Dai; Paul Shinn; Philip E Sanderson; Peter R Williamson; Karen M Frank; Wei Zheng Journal: Emerg Microbes Infect Date: 2016-11-09 Impact factor: 7.163